QC
TEVA icon

QCM Cayman’s Teva Pharmaceuticals TEVA Stock Holding History

QCM Cayman’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-11,629
Closed -$115K – 171
2021
Q2 		$115K Buy
+11,629
New +$123K 0.3% 107
2021
Q1 		– Sell
-15,718
Closed -$152K – 285
2020
Q4 		$152K Buy
15,718
+2,941
+23% +$28.2K 0.16% 243
2020
Q3 		$115K Buy
+12,777
New +$135K 0.2% 159
2018
Q2 		– Sell
-13,209
Closed -$226K – 161
2018
Q1 		$226K Buy
+13,209
New +$258K 0.59% 70
2017
Q2 		– Sell
-16,644
Closed -$534K – 389
2017
Q1 		$534K Buy
+16,644
New +$568K 0.1% 187
2015
Q1 		– Sell
-4,476
Closed -$257K – 266
2014
Q4 		$257K Buy
+4,476
New +$249K 0.11% 142

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

QCM Cayman's TEVA Position: Q3 2021 in Review

QCM Cayman sold out of Teva Pharmaceuticals (TEVA) in Q3 2021, closing a stake of 11,629 shares — an estimated $115K sold.

QCM Cayman first reported a position in TEVA in Q4 2014 and held it in 6 quarters. The position peaked at $534K in Q1 2017. 429 funds tracked by Wall St. Rank hold TEVA as of Q3 2021.

  • QCM Cayman reported no remaining Teva Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • QCM Cayman sold 11,629 Teva Pharmaceuticals shares in Q3 2021, an estimated $115K.
  • QCM Cayman first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 6 quarters.
  • QCM Cayman's Teva Pharmaceuticals position peaked at $534K in Q1 2017.
  • 429 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2021.

Based on QCM Cayman's 13F filing for Q3 2021, filed 1 Nov 2021.